UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 39,923 Shares of argenx SE (NASDAQ:ARGX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in argenx SE (NASDAQ:ARGX - Free Report) by 4,344.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,842 shares of the company's stock after purchasing an additional 39,923 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.07% of argenx worth $22,140,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. Profund Advisors LLC boosted its position in argenx by 3.0% in the second quarter. Profund Advisors LLC now owns 973 shares of the company's stock worth $418,000 after purchasing an additional 28 shares during the last quarter. Raymond James Trust N.A. boosted its holdings in shares of argenx by 6.0% in the 3rd quarter. Raymond James Trust N.A. now owns 495 shares of the company's stock worth $268,000 after buying an additional 28 shares during the last quarter. Wealth Alliance grew its position in argenx by 4.8% during the second quarter. Wealth Alliance now owns 628 shares of the company's stock valued at $270,000 after buying an additional 29 shares during the period. GAMMA Investing LLC grew its position in argenx by 51.3% during the second quarter. GAMMA Investing LLC now owns 118 shares of the company's stock valued at $51,000 after buying an additional 40 shares during the period. Finally, Sequoia Financial Advisors LLC grew its position in argenx by 3.1% during the second quarter. Sequoia Financial Advisors LLC now owns 1,713 shares of the company's stock valued at $737,000 after buying an additional 52 shares during the period. 60.32% of the stock is owned by institutional investors.

argenx Trading Down 0.5 %

Shares of ARGX traded down $3.01 during mid-day trading on Friday, reaching $623.11. 154,401 shares of the stock traded hands, compared to its average volume of 309,078. The firm has a fifty day moving average price of $574.53 and a 200 day moving average price of $505.00. The company has a market cap of $37.62 billion, a price-to-earnings ratio of -708.08 and a beta of 0.59. argenx SE has a 1 year low of $327.73 and a 1 year high of $630.00.

argenx (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $588.88 million during the quarter, compared to the consensus estimate of $543.29 million. During the same period in the previous year, the firm posted ($1.25) EPS. On average, sell-side analysts anticipate that argenx SE will post 2.2 EPS for the current year.

Analyst Ratings Changes

ARGX has been the subject of several research analyst reports. Truist Financial raised their price target on shares of argenx from $540.00 to $660.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. Piper Sandler raised their price target on shares of argenx from $553.00 to $620.00 and gave the stock an "overweight" rating in a research note on Friday, November 1st. Oppenheimer restated an "outperform" rating and set a $675.00 price target (up previously from $646.00) on shares of argenx in a research note on Thursday, November 21st. Raymond James restated a "strong-buy" rating and set a $605.00 price target on shares of argenx in a research note on Thursday, October 10th. Finally, JPMorgan Chase & Co. raised their price target on shares of argenx from $640.00 to $670.00 and gave the stock an "overweight" rating in a research note on Monday, November 4th. Three analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $635.42.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.